Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2020 - 2026)

Taysha Gene Therapies has disclosed Total Non-Current Liabilities across 7 years of filings, most recently posting $86.8 million for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $86.8 million, up 5.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $86.8 million (up 5.75% YoY), and the FY2025 annual result was $94.8 million, up 8.34% from the prior year.
• Total Non-Current Liabilities came in at $86.8 million for Q1 2026 at Taysha Gene Therapies, down from $94.8 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $241.1 million in Q3 2023 to a low of $52.3 million in Q2 2024.
• The 5-year median for Total Non-Current Liabilities is $96.0 million (2025), against an average of $101.8 million.
• Across the five-year window, Total Non-Current Liabilities surged 489.49% in 2022 and slumped 62.64% in 2024, its largest moves.
• Taysha Gene Therapies' Total Non-Current Liabilities stood at $121.2 million in 2022, then decreased by 20.61% to $96.2 million in 2023, then decreased by 9.03% to $87.5 million in 2024, then grew by 8.34% to $94.8 million in 2025, then declined by 8.44% to $86.8 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $86.8 million (Q1 2026), $94.8 million (Q4 2025), and $96.0 million (Q3 2025), per Business Quant data.